Isoray Q1 FY2023 revenue down 33% to $1.72M; net loss widens to $4.07M

Perspective Therapeutics, Inc.

Revenue $1.72M vs $2.56M YoY; core prostate brachytherapy revenue fell 41%.
Net loss $4.07M ($0.03 per share) vs $2.24M ($0.02) in prior year.
Gross margin dropped to 24.1% from 40.1%; isotope supply disruption cited.
Cash and equivalents $54.1M with no long-term debt; stockholders' equity $57.7M.
Pending merger with Viewpoint Molecular Targeting noted; G&A rose 69% on deal costs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Perspective Therapeutics, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: revenue $1.72 million, net income $4.07 million or ($0.03) per basic and diluted share.

Period: the first quarter of fiscal 2023 ended September 30, 2022
Revenue: $1.72 million
Net income: $4.07 million or ($0.03) per basic and diluted share
Result: reported results

Exact text from the filing

Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-026895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.